COLORADO SPRINGS, Colo., Nov. 26, 2012 /PRNewswire/ -- Cannabis Science, Inc (NASD OTC: CBIS) has appointed Michael J. Goldblatt, Ph.D., the former Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA) to the Company's Scientific Advisory Board (SAB). Dr. Goldblatt holds extensive experience in successfully pioneering next-generation technologies, including therapeutic protein and host-oriented therapeutics for infectious disease. Dr. Goldblatt is a General Partner and the residing Chairman of the Science Board at Four Seasons Ventures (www.fsvcapital.com). He received his B.A. in Biology from Reed College and his Ph.D. and J.D. from the University of California-Davis and is admitted to practice law in New York and Washington, D.C. and with the United States Patent Bar.

Dr. Goldblatt is also the President and CEO of Functional Genetics, a privately held biotechnology Company founded in 2001 (www.functional-genetics.com). Functional Genetics focuses on the development of new antibody-based therapeutics to prevent and treat a broad spectrum of viruses including Hepatitis B and C, HIV, Herpes, and respiratory illnesses. Functional Genetics' leading candidate FGI-101-1A6 is a fully human monoclonal antibody which targets and eliminates cells that have been infected by various viruses including HIV-1 and influenza. FGI-101-1A6 has completed a Phase IA clinical trial for influenza.

Dr. Goldblatt has over 20 years of experience working in biotechnology, product development, and regulatory affairs. He served as the Science and Technology Officer at McDonald's Corporation and Director of Scientific and Regulatory Affairs at General Foods Corporation. Dr. Goldblatt has extensive knowledge and experience in the identification and commercial development of early stage technologies, including engineering, design, manufacturing, and distribution.

Dr. Goldblatt stated, "I am very pleased to join Cannabis Science's Scientific Advisory Board to help bring Cannabinoid based therapeutics for Kaposi Sarcoma and basal and squamous cell carcinomas through current pre-clinical development to international market approvals. Cannabis Science's clinical approach to addressing unmet oncological conditions will predictably mature the vast body of preclinical discovery on the effectiveness of Cannabinoids on Cancer and viral infections."

"We are honored to have Dr. Goldblatt join the CBIS Scientific Advisory Board. His unique experience in viral drug development makes him an invaluable asset to the Cannabis Science team as we move forward in our primary focus of addressing vital medical needs," stated Robert Melamede, Ph.D., President and CEO of Cannabis Science.

About CS-TATI-1

Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About CS-S/BCC-1

Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com

or

Robert Kane, 1-561-234-6929
VP Investor Relations
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

SOURCE Cannabis Science, Inc.